These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 20842059)

  • 41. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 42. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
    Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
    Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program.
    Kozireva S; Rudevica Z; Baryshev M; Leonciks A; Kashuba E; Kholodnyuk I
    Viruses; 2018 May; 10(5):. PubMed ID: 29751565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.
    Yvon E; Del Vecchio M; Savoldo B; Hoyos V; Dutour A; Anichini A; Dotti G; Brenner MK
    Clin Cancer Res; 2009 Sep; 15(18):5852-60. PubMed ID: 19737958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
    Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
    J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
    You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
    Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
    Yu L; Huang L; Lin D; Lai X; Wu L; Liao X; Liu J; Zeng Y; Liang L; Zhang G; Wang B; Wu Z; Tao S; Liu Y; Jiao C; Chang LJ; Yang L
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2643-2652. PubMed ID: 34724115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.
    Li H; Harrison EB; Li H; Hirabayashi K; Chen J; Li QX; Gunn J; Weiss J; Savoldo B; Parker JS; Pecot CV; Dotti G; Du H
    Nat Commun; 2022 Apr; 13(1):2154. PubMed ID: 35443752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
    Di Stasi A; De Angelis B; Rooney CM; Zhang L; Mahendravada A; Foster AE; Heslop HE; Brenner MK; Dotti G; Savoldo B
    Blood; 2009 Jun; 113(25):6392-402. PubMed ID: 19377047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of CC chemokines in gammadelta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway.
    Penido C; Costa MF; Souza MC; Costa KA; Candéa AL; Benjamim CF; Henriques Md
    Int Immunol; 2008 Jan; 20(1):129-39. PubMed ID: 18056919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL; Albelda SM; June CH
    Cancer Res; 2010 Nov; 70(22):9053-61. PubMed ID: 20926399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.
    Straathof K; Flutter B; Wallace R; Jain N; Loka T; Depani S; Wright G; Thomas S; Cheung GW; Gileadi T; Stafford S; Kokalaki E; Barton J; Marriott C; Rampling D; Ogunbiyi O; Akarca AU; Marafioti T; Inglott S; Gilmour K; Al-Hajj M; Day W; McHugh K; Biassoni L; Sizer N; Barton C; Edwards D; Dragoni I; Silvester J; Dyer K; Traub S; Elson L; Brook S; Westwood N; Robson L; Bedi A; Howe K; Barry A; Duncan C; Barone G; Pule M; Anderson J
    Sci Transl Med; 2020 Nov; 12(571):. PubMed ID: 33239386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.
    Lau G; Labrecque J; Metz M; Vaz R; Fricker SP
    J Biol Chem; 2015 Apr; 290(17):11041-51. PubMed ID: 25767113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice.
    Parente-Pereira AC; Burnet J; Ellison D; Foster J; Davies DM; van der Stegen S; Burbridge S; Chiapero-Stanke L; Wilkie S; Mather S; Maher J
    J Clin Immunol; 2011 Aug; 31(4):710-8. PubMed ID: 21505816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of antigen specificity and migratory capacity of memory T cells in rheumatoid arthritis.
    Shadidi KR; Thompson KM; Henriksen JE; Natvig JB; Aarvak T
    Scand J Immunol; 2002 Mar; 55(3):274-83. PubMed ID: 11940234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis.
    Segerer S; Cui Y; Hudkins KL; Goodpaster T; Eitner F; Mack M; Schlöndorff D; Alpers CE
    J Am Soc Nephrol; 2000 Dec; 11(12):2231-2242. PubMed ID: 11095646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.